The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Clinical Cancer Research

• Publication date

  2005-01-15

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  PMID 15701880
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.

  2004cited by this paper
• Coregulator function: a key to understanding tissue specificity of selective receptor modulators.

  2004cited by this paper
• Estrogen-Related Receptor α in Human Breast Carcinoma as a Potent Prognostic Factor

  2004cited by this paper
• Rapid extranuclear signaling by the estrogen receptor (ER): MNAR couples ER and Src to the MAP kinase signaling pathway.

  2003cited by this paper
• Estrogen receptor-α mediates the brain antiinflammatory activity of estradiol

  2003cited by this paper
• Tamoxifen for Prevention of Breast Cancer

  2003cited by this paper
• Evaluation of an estrogen receptor-beta agonist in animal models of human disease.

  2003cited by this paper
• Aromatase inhibitors in breast cancer.

  2003cited by this paper
• Evaluation of an Estrogen Receptor-β Agonist in Animal Models of Human Disease

  2003cited by this paper
• Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.

  2003cited by this paper
• Expression of peroxisome‐proliferator activated receptor‐gamma (PPARγ) and the PPARγ co‐activator, PGC‐1, in human breast cancer correlates with clinical outcomes

  2003cited by this paper
• Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol.

  2002cited by this paper
• ERbeta has nongenomic action in caveolae.

  2002cited by this paper
• Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer.

  2002cited by this paper
• Molecular Determinants for the Tissue Specificity of SERMs

  2002cited by this paper
• Estrogen-related Receptor α and Estrogen-related Receptor γ Associate with Unfavorable and Favorable Biomarkers, Respectively, in Human Breast Cancer

  2002cited by this paper
• Aromatase inhibitors in breast cancer.

  2002cited by this paper
• ERβ Has Nongenomic Action in Caveolae

  2002cited by this paper
• Structural insights into the mode of action of a pure antiestrogen.

  2001cited by this paper
• Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor.

  2001cited by this paper
• The Human Estrogen Receptor-α Is a Ubiquitinated Protein Whose Stability Is Affected Differentially by Agonists, Antagonists, and Selective Estrogen Receptor Modulators*

  2001cited by this paper
• Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial.

  2001cited by this paper
• Estrogen receptor (ER) b, a modulator of ERa in the uterus

  2000cited by this paper
• Estrogen receptor (ER) , a modulator of ER in the uterus

  2000cited by this paper
• The Estrogen Receptor β-Isoform (ERβ) of the Human Estrogen Receptor Modulates ERα Transcriptional Activity and Is a Key Regulator of the Cellular Response to Estrogens and Antiestrogens1.

  1999cited by this paper
• The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens.

  1999cited by this paper
• Nuclear receptor coregulators: cellular and molecular biology.

  1999cited by this paper
• Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium.

  1999cited by this paper
• Comparative analyses of mechanistic differences among antiestrogens.

  1999cited by this paper
• Peptide antagonists of the human estrogen receptor.

  1999cited by this paper
• Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta.

  1999cited by this paper
• The Molecular Pharmacology of SERMs.

  1999cited by this paper
• Comparative Analyses of Mechanistic Differences Among Antiestrogens1.

  1999cited by this paper
• The Philadelphia story: the 22q11.2 deletion: report on 250 patients.

  1999cited by this paper
• Structure of the ligand‐binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist

  1999cited by this paper
• The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen.

  1998cited by this paper
• Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone.

  1997cited by this paper
• Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen.

  1997cited by this paper
• AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer.

  1997cited by this paper
• Cloning of a novel receptor expressed in rat prostate and ovary.

  1996cited by this paper
• Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol.

  1996cited by this paper
• Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens.

  1995cited by this paper
• Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta

  1995cited by this paper
• When tamoxifen turns bad.

  1995cited by this paper
• Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells.

  1995cited by this paper
• Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.

  1995cited by this paper
• 3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats.

  1994cited by this paper
• Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain.

  1993cited by this paper
• Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone.

  1993cited by this paper
• Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation.

  1992cited by this paper
• Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer.

  1992cited by this paper
• Increased osteoclast development after estrogen loss: mediation by interleukin-6.

  1992cited by this paper
• A potent specific pure antiestrogen with clinical potential.

  1991cited by this paper
• Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen.

  1988cited by this paper
• A new derivative of triphenylethylene: effect on implantation and mode of action in rats.

  1967cited by this paper
• Cloning of a novel estrogen receptor expressed in rat prostate and ovary

  year unknowncited by this paper

• Current Therapeutic Opportunities for Estrogen Receptor Mutant Breast Cancer

  2024cites this paper
• Understanding the mechanistic potential of plant based phytochemicals in management of postmenopausal osteoporosis.

  2023cites this paper
• Skeletal and gene-regulatory functions of nuclear sex steroid hormone receptors

  2022cites this paper
• The Adrenal Cortex and Its Disorders

  2021cites this paper
• SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

  2020cites this paper
• Estrogen and sex-dependent loss of the vocal learning system in female zebra finches

  2020cites this paper
• Tamoxifen/raloxifene loaded liposomes for oral treatment of breast cancer

  2020cites this paper
• MOLECULAR CANCER THERAPEUTICS | SMALL MOLECULE THERAPEUTICS SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

  2020cites this paper
• Distinct Approaches of Raloxifene: Its Far-Reaching Beneficial Effects Implicating the HO-System

  2020cites this paper
• Estrogen signaling: An emanating therapeutic target for breast cancer treatment.

  2019cites this paper
• Development of Liposome Formulations of Tamoxifen and Assessment of Caco-2 Cell Transportation Properties

  2018cites this paper
• Differential recruitment of co-regulatory proteins to the human estrogen receptor 1 in response to xenoestrogens.

  2016cites this paper
• Differential recruitment of co-regulatory proteins to the human estrogen receptor 1 in 1 response to xenoestrogens 2 3

  2016cites this paper
• Selective Estrogen Receptor Modulators – an Update (Joint Statement by the German Society for Gynecological Endocrinology and Reproductive Medicine [DGGEF] and the German Professional Association of Gynecologists [BVF])

  2016cites this paper
• Clomiphene citrate down-regulates estrogen receptor-α through the ubiquitin-proteasome pathway in a human endometrial cancer cell line.

  2016cites this paper
• Selektive Östrogenrezeptormodulatoren (SERM)

  2015cites this paper
• The Effectiveness of Raloxifene-Loaded Liposomes and Cochleates in Breast Cancer Therapy

  2015cites this paper
• Induction of the CLOCK Gene by E2-ERα Signaling Promotes the Proliferation of Breast Cancer Cells

  2014influential citation
• Antitumoral and MMP-2 inhibition activity of raloxifene or tamoxifen loaded nanoparticles containing dimethyl-β-cyclodextrin

  2014cites this paper
• Endocrine resistance in breast cancer: biological mechanisms and clinical implications to develop new treatment strategies

  2013cites this paper
• Estrogen Receptor α (ERα) and Estrogen Related Receptor α (ERRα) are both transcriptional regulators of the Runx2-I isoform.

  2013cites this paper
• Prise en charge thérapeutique des cancers du sein infiltrants localisés

  2013cites this paper
• Drug targets to improve the outcome of hormonal adjuvant therapy in breast and prostate cancers

  2013cites this paper
• Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy.

  2012cites this paper
• Utilizing the Estrogen Receptor Ligand-Binding Domain for Controlled Protein Translocation to the Insoluble Fraction

  2012cites this paper
• The evolution of selective estrogen receptor modulators in osteoporosis therapy

  2012cites this paper
• Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance.

  2011cites this paper
• In Vivo Treatments with Fulvestrant and Anastrozole Differentially Affect Gene Expression in the Rat Efferent Ductules1

  2011cites this paper
• Genistein induces enhanced growth promotion in ER-positive/erbB-2-overexpressing breast cancers by ER-erbB-2 cross talk and p27/kip1 downregulation.

  2010cites this paper
• Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant

  2010cites this paper
• Differential Control of TGM2 Expression by Oestrogen Receptor/SERMs.

  2010cites this paper
• Genomic Effects of Hormonal Adjuvant Therapies that Could Support the Emergence of Drug Resistance in Breast Cancer

  2010influential citation
• The role of biotransformation in the estrogenicity of xenobiotics

  2010cites this paper
• Classifi cation of anti-estrogens according to intramolecular FRET effects on phospho-mutants of ERα

  2009cites this paper
• Application of Screening Methods, Shape Signatures and Engineered Biosensors in Early Drug Discovery Process

  2009cites this paper
• Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance

  2009cites this paper
• Genetic polymorphisms in the estrogen receptor beta (ESR2) gene and the risk of epithelial ovarian carcinoma

  2009cites this paper
• Effects of a diet rich in sesame (Sesamum indicum) pericarp on the expression of oestrogen receptor α and oestrogen receptor β in rat prostate and uterus

  2009cites this paper
• Differential mass spectrometry of rat plasma reveals proteins that are responsive to 17beta-estradiol and a selective estrogen receptor modulator PPT.

  2008cites this paper
• Selective Estrogen Receptor Modulators: An Update on Recent Clinical Findings

  2008cites this paper
• Reversed-phase liquid chromatography coupled on-line to estrogen receptor bioaffinity detection based on fluorescence polarization

  2008cites this paper
• Cleaved thioredoxin fusion protein enables the crystallization of poorly soluble ERalpha in complex with synthetic ligands.

  2008cites this paper
• Estrogen-induced and TAFII30-mediated gene repression by direct recruitment of the estrogen receptor and co-repressors to the core promoter and its reversal by tamoxifen

  2007cites this paper
• Effects of estradiol and 4-hydroxytamoxifen on the conformation, thermal stability, and DNA recognition of estrogen receptor beta.

  2007cites this paper
• Classification of anti-estrogens according to intramolecular FRET effects on phospho-mutants of estrogen receptor α

  2007cites this paper
• Ligand Binding to the Androgen Receptor Induces Conformational Changes That Regulate Phosphatase Interactions

  2007cites this paper
• Receptor signaling in cancer.

  2007cites this paper
• Danggui Buxue Tang – A Chinese herbal decoction activates the phosphorylations of extracellular signal‐regulated kinase and estrogen receptor α in cultured MCF‐7 cells

  2007cites this paper
• The classical and a non-classical pathways associated with NF-kappaB are involved in estrogen-mediated regulation of calbindin-D9k gene in rat pituitary cells.

  2007cites this paper
• Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis.

  2007cites this paper
• Epidemiology and Risk Factors of Cardiovascular Disease in Postmenopausal Women

  2007cites this paper
• PTEN regulates phospholipase D and phospholipase C.

  2007cites this paper
• Molecular mechanism of regulation of the calcium-binding protein calbindin-D9k,and its physiological role(s) in mammals: a review of current research

  2007cites this paper
• Danggui buxue tang--a Chinese herbal decoction activates the phosphorylations of extracellular signal-regulated kinase and estrogen receptor alpha in cultured MCF-7 cells.

  2007cites this paper
• Linking ligand-induced alterations in androgen receptor structure to differential gene expression: a first step in the rational design of selective androgen receptor modulators.

  2006cites this paper
• Novel Targets and Therapeutics for Bone Loss

  2006cites this paper
• A 62-year-old woman with a new diagnosis of breast cancer.

  2006cites this paper
• Estrogens, selective estrogen receptor modulators, and a selective estrogen receptor down-regulator inhibit endothelial production of tissue factor pathway inhibitor 1

  2006cites this paper
• A FRET profile of modifications in Estrogen Receptor α associated with resistance to anti-estrogens Submitted 10

  2006cites this paper
• Estrogen stimulation of COX-2-derived PGI2 confers atheroprotection.

  2005cites this paper
• Conformational dynamics of estrogen receptors alpha and beta as revealed by intrinsic tryptophan fluorescence and circular dichroism.

  2005cites this paper
• Award Number: DAMD17-03-1-0674 TITLE: Structural Determination of Certain Novel ER Complexes

  2005cites this paper
• Structural basis for an unexpected mode of SERM-mediated ER antagonism.

  2005cites this paper
• Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer.

  2005cites this paper
• Conformational dynamics of estrogen receptors (cid:1) and (cid:2) as revealed by intrinsic tryptophan fluorescence and circular dichroism

  year unknowncites this paper
• Estrogen Receptor Modulators

  year unknowncites this paper